P3 Health Partners (NASDAQ:PIII) Releases Quarterly Earnings Results, Beats Expectations By $5.17 EPS

Posted by on May 16th, 2026

P3 Health Partners (NASDAQ:PIII – Get Free Report) announced its quarterly earnings data on Thursday. The company reported $0.32 EPS for the quarter, topping the consensus estimate of ($4.85) by $5.17, FiscalAI reports. The company had revenue of $386.39 million during the quarter, compared to the consensus estimate of $391.45 million. P3 Health Partners had a negative net margin of 8.57% and a negative return on equity of 302.33%.

Here are the key takeaways from P3 Health Partners’ conference call:

  • P3 reported $26 million of adjusted EBITDA in Q1, well above internal expectations, and raised its full-year 2026 outlook to $20 million-$60 million as execution improved.
  • The company said its Medicare Advantage medical cost trend was roughly flat versus the full-year 2025 baseline, which it framed as a meaningful differentiator versus peers guiding to 7%+ trend.
  • Management highlighted stronger payer economics, including about a 15% year-over-year improvement in MA funding rates and delegated functions covering 63% of membership in 2026.
  • The company said its balance sheet improved after roughly $250 million of debt was converted to preferred equity, and it believes it now exceeds the Nasdaq minimum stockholders’ equity requirement.
  • Membership declined year over year to about 106,000 at-risk lives as P3 exited lower-economics arrangements, but total lives under management reached about 135,000 including service arrangements and a new Nebraska partnership.

P3 Health Partners Price Performance

Shares of NASDAQ PIII traded up $7.26 during mid-day trading on Friday, reaching $11.29. 65,159,971 shares of the company’s stock were exchanged, compared to its average volume of 134,546. The firm has a market capitalization of $81.43 million, a price-to-earnings ratio of -0.29 and a beta of 0.48. P3 Health Partners has a 52 week low of $1.52 and a 52 week high of $14.35. The firm has a 50-day moving average price of $3.05 and a two-hundred day moving average price of $3.85.

Analyst Ratings Changes

Several research firms recently issued reports on PIII. Lake Street Capital reissued a “buy” rating and issued a $14.00 price target (up from $4.00) on shares of P3 Health Partners in a research report on Friday. TD Cowen reduced their price target on shares of P3 Health Partners from $8.00 to $3.00 and set a “hold” rating for the company in a research report on Thursday, April 2nd. Weiss Ratings reissued a “sell (e+)” rating on shares of P3 Health Partners in a research report on Tuesday, April 21st. Finally, UBS Group set a $14.00 price target on shares of P3 Health Partners in a research report on Friday. One research analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $10.33.

View Our Latest Stock Analysis on PIII

P3 Health Partners News Roundup

Here are the key news stories impacting P3 Health Partners this week:

  • Positive Sentiment: P3 Health Partners reported Q1 2026 earnings of $0.32 per share, beating expectations for a large loss, which appears to be the main catalyst behind the stock’s surge. P3 Health Partners (PIII) Stock Surges Over 42% After Hours: Here’s Why
  • Positive Sentiment: The company’s revenue for the quarter was $386.39 million, roughly in line with estimates, helping support investor confidence that operating results were better than expected overall. P3 Health Partners earnings press release
  • Neutral Sentiment: Trading in PIII was halted several times for LULD pauses, indicating extreme volatility and a fast-moving price reaction to the earnings news.
  • Neutral Sentiment: Commentary following the report highlighted that the stock was reacting to a narrower-than-expected loss and a sharp after-hours move, underscoring speculation and momentum trading rather than a fresh business announcement. P3 Health Partners (PIII) stock surges over 42% after hours: Here’s why
  • Negative Sentiment: Despite the earnings beat, P3 Health Partners still reported a negative net margin and negative return on equity, so the underlying turnaround story remains unproven.

About P3 Health Partners

(Get Free Report)

P3 Health Partners is a healthcare technology and services company that delivers data-driven solutions to support health plans in improving quality measures, risk adjustment accuracy and operational efficiency. The company’s platform integrates advanced analytics, reporting capabilities and workflow automation to help clients optimize performance across value-based care programs and regulatory requirements.

The company’s core offerings include quality measurement and reporting for HEDIS, STAR and other performance frameworks, risk adjustment coding and audit services, and population health analytics.

Read More

Earnings History for P3 Health Partners (NASDAQ:PIII)

Receive News & Ratings for P3 Health Partners Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for P3 Health Partners and related companies with MarketBeat.com's FREE daily email newsletter.